Analyst Price Targets — LENZ
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 12, 2026 10:51 am | — | Piper Sandler | $7.00 | $5.21 | TheFly | Lenz Therapeutics price target lowered to $7 from $12 at Piper Sandler |
| May 12, 2026 9:10 am | — | Piper Sandler | $12.00 | $9.99 | TheFly | Lenz Therapeutics downgraded to Neutral from Overweight at Piper Sandler |
| October 27, 2025 10:52 am | Matthew Caufield | H.C. Wainwright | $56.00 | $30.87 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on LENZ Therapeutics Inc (LENZ) |
| October 10, 2025 10:47 am | — | Piper Sandler | $67.00 | $46.25 | TheFly | Lenz Therapeutics price target raised to $67 from $51 at Piper Sandler |
| April 14, 2025 10:36 am | Biren Amin | Piper Sandler | $51.00 | $23.24 | TheFly | Lenz Therapeutics assumed with an Overweight at Piper Sandler |
| August 15, 2024 8:44 am | Joseph Catanzaro | Piper Sandler | $36.00 | $22.25 | StreetInsider | Piper Sandler Reiterates Overweight Rating on LENZ Therapeutics Inc (LENZ) |
| August 15, 2024 4:58 am | Yigal Nochomovitz | Citigroup | $32.00 | $23.50 | StreetInsider | LENZ Therapeutics Inc (LENZ) PT Lowered to $32 at Citi |
Latest News for LENZ
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the "Company") (NASDAQ: LENZ).
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
LENZ Therapeutics is rated a 'Strong Buy' with a fair value estimate of $21.3, reflecting ~266% upside from current levels. I model peak US Vizz sales at $375M, using a 5-pack annualized purchase rate and 30% market share, with conservative international assumptions. LENZ's speculative nature persists due to single-product risk, high SG&A, uninsured status, and rising competition; position sizing remains limited.
NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("Lenz" or the "Company") (NASDAQ: LENZ).
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. (“Lenz” or the “Company”) (NASDAQ: LENZ).
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LENZ.
U.S. House Trading
No House trades found for LENZ.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.